European Innovation Council

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

David Malo Jean

Director

Past deals in Western Europe

VSORA

Venture Round in 2025
VSORA develops digital signal processing IP and chips for 5G networks, featuring a multicore DSP architecture that removes the need for DSP coprocessors and a shared DSP development flow that unites signal processing and software engineers in one environment to speed time-to-market. The company aims to boost DSP computing power while reducing power consumption, improving system performance, and shrinking silicon footprint. Based in France, founded in 2015 by veteran DSP engineers, VSORA serves chipmakers designing next-generation digital communications systems.

AMT Medical

Series B in 2025
AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.

Sparrow Quantum

Series A in 2025
Sparrow Quantum specializes in developing deterministic single-photon sources for advancing light-matter interfaces in quantum technologies. With a focus on high efficiency, purity, indistinguishability, and outcoupling, the company's technology is based on over two decades of research at the Niels Bohr Institute.

Marvel Fusion

Series B in 2025
Marvel Fusion develops fusion energy technology using a laser-based reactor. Its innovative approach offers clean, safe, and reliable energy solutions, aiming to commercialize baseload fusion electrical power.

Stablepharma

Grant in 2025
Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.

Wooptix

Series C in 2025
Founded in Madrid, Spain in 2014, Wooptix develops innovative imaging technologies. The company specializes in creating three-dimensional modulation of images for enhanced volumetric photography and videography, enabling advanced image post-processing.

QDI systems

Venture Round in 2025
QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

QDI systems

Grant in 2025
QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

Photon IP

Grant in 2025
Photon IP is a Dutch deeptech company based in Eindhoven. It specializes in developing advanced photonics technologies for various applications.

GBM Works

Seed Round in 2024
GBM Works is a Netherlands-based company that develops offshore wind turbine foundation installation technologies. Founded in 2016 and based in The Hague, it focuses on methods for installing foundations with minimal environmental impact, including a silent installation approach designed to reduce noise pollution and disruption to marine life. The company's solutions aim to enable faster deployment of offshore wind projects while supporting sustainability goals in renewable energy.

Onward

Grant in 2024
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Inbrain Neuroelectronics

Series B in 2024
Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

National University of Ireland, Maynooth

Grant in 2024
Maynooth University is internationally recognised for quality and value of Their research and scholarship and Their dedication and commitment to teaching and Their students. Part of the NUI and formally established as an autonomous university in 1997, Maynooth University traces its origins to the foundation of the Royal College of St. Patrick in 1795, drawing inspiration from a heritage that includes over 200 years of education and scholarship. The University is a place of lively contrasts. It is a modern institution, dynamic, rapidly-growing, research-led and engaged, yet grounded in historic academic strengths and scholarly traditions.

Axelera AI

Series B in 2024
Axelera AI specializes in developing hardware and software platforms designed to accelerate artificial intelligence tasks, particularly for edge computing. Its flagship product, the Metis™ AI Platform, integrates both hardware and software components to deliver high-performance, energy-efficient AI inference solutions. The company is headquartered in Eindhoven with R&D offices in Belgium, Switzerland, and Italy.

Qblox

Series A in 2024
Qblox is a Dutch scaleup specializing in quantum technology, focused on developing patented solutions for the scalable control of quantum computers. The company designs and manufactures modular control hardware that simplifies the experimental setups involving qubits, employing a distributed processor architecture to enhance gate fidelities. By advancing electronics with improved noise and drift performance, Qblox enables scientists to minimize crosstalk and achieve low-latency arbitrary control flows while optimizing measurement efficiency in dynamic readout conditions. The company aims to address the scientific and engineering challenges that must be overcome to transition from prototype quantum computers to powerful, practical quantum processors.

King's College London

Grant in 2024
King's College London is a public research university in London, United Kingdom, and a constituent college of the University of London. Founded in 1829 by King George IV and the Duke of Wellington, it operates from multiple central London campuses and a campus in Denmark Hill, with a strong emphasis on medical and biomedical research and education. The institution supports a large community of students and staff and is known for its extensive graduate and postgraduate programmes. It is a founding member of the King's Health Partners academic health sciences centre and participates in major research and academic networks, including the Russell Group and Universities UK.

Tilkal

Venture Round in 2024
Tilkal develops a software infrastructure that organizes traceability across various supply chain stakeholders. Founded in 2017, the company is headquartered in Paris, France.

E-peas

Venture Round in 2024
E-peas SA is a Belgian company established in 2014, specializing in the design and manufacturing of electronic systems that provide energy autonomy for Internet of Things (IoT) applications. The company develops innovative energy harvesting solutions that enable devices to draw energy from various ambient sources, including solar, thermal, vibration, and radiofrequency. E-peas produces energy harvesting power management integrated circuits (PMICs) and microcontrollers that enhance the performance and longevity of IoT devices by either extending battery life or eliminating the need for batteries altogether. Their technology caters to a wide range of sectors, including home automation, healthcare, retail, and agriculture, thereby facilitating the creation of smarter and more energy-efficient connected devices. Headquartered in Mont-Saint-Guibert, Belgium, E-peas aims to transform the landscape of portable energy solutions.

Ability Pharmaceuticals

Venture Round in 2024
Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Multiverse Computing

Series A in 2024
Founded in 2019 with headquarters in San Sebastian, Spain, Multiverse Computing develops quantum computing software tailored to solve complex real-world challenges. Its software leverages probabilistic technology for portfolio optimization, risk analysis, and market simulation, serving clients across industries such as finance, energy, manufacturing, and logistics.

Daze

Series A in 2024
Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

Palobiofarma

Venture Round in 2024
Palobiofarma is a Spanish biotechnology company based in Barcelona, focused on discovering and developing new medicines by modulating adenosine receptors. It aims to be a leader in European adenosine receptor drug discovery, using medicinal chemistry and in vitro pharmacology to identify selective adenosine receptor modulators, with potential applications in treating advanced prostate cancer.

NETRIS Pharma

Series A in 2023
NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Antabio

Series B in 2023
Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

Ignion

Venture Round in 2023
Founded in 2015, Ignion specializes in designing and manufacturing antennas tailored for mobile and wireless connectivity. Their off-the-shelf antennas cater to Internet of Things devices, mobile connectivity, and short-range wireless systems, facilitating seamless integration within industrial designs.

ResoTher Pharma

Grant in 2023
ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

VSORA

Grant in 2023
VSORA develops digital signal processing IP and chips for 5G networks, featuring a multicore DSP architecture that removes the need for DSP coprocessors and a shared DSP development flow that unites signal processing and software engineers in one environment to speed time-to-market. The company aims to boost DSP computing power while reducing power consumption, improving system performance, and shrinking silicon footprint. Based in France, founded in 2015 by veteran DSP engineers, VSORA serves chipmakers designing next-generation digital communications systems.

SolasCure

Grant in 2023
Founded in 2017, SolasCure is a biotechnology company based in Wales, UK. It specializes in developing innovative hydrogel treatments for patients with chronic wounds. Its flagship product, Aurase, facilitates wound debridement, removing dead or infected tissue to enhance healing.

FarmInsect

Series A in 2023
FarmInsect GmbH, established in 2019 and headquartered in Bergkirchen, Germany, specializes in automated insect breeding systems. The company develops machines and IoT solutions that enable regional farmers to rear insects on-site for use as animal feed, primarily for chickens, pigs, and fish. This sustainable approach aims to replace imported soy or fishmeal with locally produced protein feed, thereby enhancing the efficiency of animal husbandry while reducing environmental impact.

Nanogence

Venture Round in 2023
Founded in 2017, Nanogence specializes in developing novel material solutions for the construction sector. It focuses on creating synthetic, tailor-made materials that enhance performance and reduce carbon emissions in applications such as construction, pharmaceuticals, and mobility.

Epigene Labs

Convertible Note in 2023
Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

Swisspod Technologies

Grant in 2023
Founded in 2019, Swisspod Technologies specializes in designing and developing Hyperloop vessels for tube-based transportation systems. The company aims to create energy-efficient, fully-electric pods, harnessing high-quality Swiss engineering to facilitate sustainable and efficient high-speed travel between cities.

Microsure

Series B in 2023
Founded in 2014, Microsure specializes in enhancing microsurgical procedures. Its flagship product is a motion stabilizer system designed by and for microsurgeons to overcome physical limitations and improve surgical precision. This technology has successfully been used in clinical trials, with the aim of increasing treatment options for patients.

Xeltis

Series D in 2023
Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Inbrain Neuroelectronics

Grant in 2023
Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

ONO

Convertible Note in 2023
Creating transformative change in urban mobility, making our cities cleaner and more enjoyable. We first focus on urban logistics, moving goods around the city in ways that are sustainable, efficient and cost-effective. Our vehicle and its modular platform system, with easily swappable modular units, meets the needs of city logistics. From moving food to flowers to furniture, the possibilities are endless. ONO’s founders, pioneer in e-mobility solutions, Beres Seelbach, former head of design at Mercedes and Volkswagen, Murat Günak, and light electric vehicle expert and engineer, Philipp Kahle, sought to rethink and reshape modern urban transportation. They put together a forward-thinking group of designers, engineers and creative thinkers who shared their vision of transforming urban mobility. ONO is a Berlin-based e-mobility company introducing a whole new category of emissions-free vehicle: the Pedal Assisted Transporter (PAT), combining the flexibility of a bicycle with the capacity and durability of a van. We offer environmentally friendly urban logistics solutions designed and optimised for cities of today.

Scipio Bioscience

Convertible Note in 2023
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Wooptix

Series B in 2023
Founded in Madrid, Spain in 2014, Wooptix develops innovative imaging technologies. The company specializes in creating three-dimensional modulation of images for enhanced volumetric photography and videography, enabling advanced image post-processing.

Wooptix

Grant in 2023
Founded in Madrid, Spain in 2014, Wooptix develops innovative imaging technologies. The company specializes in creating three-dimensional modulation of images for enhanced volumetric photography and videography, enabling advanced image post-processing.

ADmit Therapeutics

Venture Round in 2023
ADmit Therapeutics is a biotechnology company that develops diagnostic tests for early detection of Alzheimer’s disease. Its blood-based assay uses epigenetic analysis to assess mitochondrial DNA methylation, including methylcytosines, through next-generation sequencing, and does not rely on beta-amyloid or tau markers. The test is intended to aid pharmaceutical research by enabling early diagnosis and streamlined drug development. The company was founded in 2017 and is based in Begues, Spain.

Plasmacure

Convertible Note in 2023
Plasmacure develops a cold plasma technology to treat chronic wounds, with a focus on diabetic foot ulcers. Based in Eindhoven, the Netherlands, the company aims to stimulate healing by killing bacteria, promoting cell proliferation, and improving microcirculation, thereby reducing the risk of amputation and enhancing patient quality of life.

EBAMed

Series A in 2023
EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

TreaTech

Series A in 2023
TreaTech is a Swiss cleantech company established in 2015 by engineers from the École Polytechnique Fédérale de Lausanne (EPFL). The company specializes in developing catalytic hydrothermal gasification (cHTG) technology that offers an innovative approach to wastewater treatment. This thermochemical process effectively transforms various types of liquid waste, including sewage sludge, into valuable by-products such as renewable gas, clean water, and mineral salts. TreaTech's solutions focus on eco-friendly waste disposal, aligning with sustainable development and circular economy principles. By recycling wastewater and its by-products, TreaTech enables clients to manage waste more sustainably while generating resources like fertilizers and biogas.

Sparrow Quantum

Seed Round in 2023
Sparrow Quantum specializes in developing deterministic single-photon sources for advancing light-matter interfaces in quantum technologies. With a focus on high efficiency, purity, indistinguishability, and outcoupling, the company's technology is based on over two decades of research at the Niels Bohr Institute.

Naco

Grant in 2023
Naco Technologies Ltd is a manufacturer and supplier of advanced nano-coating technologies, specializing in high-performance coatings for various industries including tooling, automotive, aerospace, and microchip production. Founded in 2009 and headquartered in Riga, Latvia, Naco develops multilayer and multicomponent coatings that enhance equipment performance by providing oil-enhanced, wear-protective, thermal barrier, and liquid-repellent properties. The company plays a significant role in the hydrogen sector by creating specialized coatings for Green Hydrogen systems, such as electrolyzers and fuel cells, which improve the reliability of these systems while minimizing the use of costly and scarce materials. In 2015, Naco Technologies was acquired by the Schaeffler Group, a Germany-based company, further strengthening its capabilities and market reach.

Bluedrop Medical

Venture Round in 2023
Founded in 2014, Bluedrop Medical develops an IoT-enabled device for early detection of diabetic foot ulcers. Its home-based system scans patients' feet daily, sends data to the cloud for analysis, and alerts healthcare providers to potential abnormalities, reducing amputation risks.

Samplix

Grant in 2023
Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Samplix

Venture Round in 2023
Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Nemysis

Grant in 2023
Nemysis is a Dublin-based specialty pharmaceutical company focused on developing and manufacturing food supplements, medical matrix products and prescription medicines. Founded in 2005, it pursues a staged development strategy to commercialize OTC and prescription products across different market segments addressing nutritional disorders and deficiencies. The company develops products such as a novel nanoparticulate oral iron supplement with a unique absorption mechanism to treat iron deficiency or anemia while minimizing gastrointestinal side effects, and glutenase capable of functioning in both the stomach and intestine to protect individuals with celiac disease or gluten sensitivity from inadvertent gluten exposure.

nyris

Venture Round in 2023
nyris is a visual search platform provider that enables users to find products and objects in images and videos using AI and neural networks. The platform serves multiple industries, including retail and e-commerce, industrial and manufacturing, media and entertainment, and financial services, by delivering fast, unified search results and improved discovery. Founded in 2015 and headquartered in Berlin with a second location in Düsseldorf, nyris serves customers across more than 50 countries.

Wingtra

Series B in 2023
Wingtra is a Swiss drone manufacturer that designs the WingtraOne, a vertical take-off and landing VTOL fixed-wing drone that combines plane-like efficiency with VTOL versatility to deliver high-precision aerial data for surveying, mapping, and infrastructure projects. The platform supports sectors including construction, mining, agriculture, forestry, environmental monitoring, urban planning, and land management by capturing detailed data over large areas. Founded in 2014 and launching its market-ready product in 2017, Wingtra serves a global customer base through a network of surveying equipment dealers, enabling professionals to digitize and monitor surroundings with reliable flight performance.

Sensius

Convertible Note in 2023
Sensius is a medical device company based in Rotterdam, Netherlands, founded in 2015. It develops a thermotherapy (hyperthermia) system for head and neck cancer that combines proprietary thermal technology with interactive software and integrated microwave sources. The device is designed by clinicians to tailor treatments, using consumable collars to target the head and neck region. The technology aims to augment standard cancer therapies such as radiotherapy and chemotherapy by improving treatment outcomes and quality of life while reducing associated side effects. Sensius markets its system to oncology clinics and is pursuing CE and FDA clearance, with early interest from potential purchasers as regulatory milestones are approached.

Sensius

Venture Round in 2023
Sensius is a medical device company based in Rotterdam, Netherlands, founded in 2015. It develops a thermotherapy (hyperthermia) system for head and neck cancer that combines proprietary thermal technology with interactive software and integrated microwave sources. The device is designed by clinicians to tailor treatments, using consumable collars to target the head and neck region. The technology aims to augment standard cancer therapies such as radiotherapy and chemotherapy by improving treatment outcomes and quality of life while reducing associated side effects. Sensius markets its system to oncology clinics and is pursuing CE and FDA clearance, with early interest from potential purchasers as regulatory milestones are approached.

Valo Therapeutics

Grant in 2023
Valo Therapeutics is an immunotherapy company focused on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Founded in 2016 and based in Oxford, United Kingdom, with an additional office in Helsinki, Finland, the company utilizes its innovative Valo Tx platform, which includes PeptiCRAd, an engineered human oncolytic adenovirus. This platform is designed to induce systemic anti-tumor T cell responses by transforming oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without requiring the production of multiple genetically modified viruses. Valo Therapeutics is also advancing other neoantigen strategies, including PeptiENV, in collaboration with Professor Vincenzo Cerullo from the University of Helsinki, to enhance therapeutic responses against various cancer types.

Kvantify

Grant in 2023
Founded in 2022, Kvantify is headquartered in Copenhagen, Denmark. It specializes in quantum computing management software, offering solutions to address computational challenges across various industries such as life sciences, financial services, and logistics.

N2 Applied

Private Equity Round in 2023
N2 Applied is a Norwegian technology company focused on enabling farmers to produce their own sustainable fertilizer through an innovative process that utilizes slurry, air, and electricity. The company is in the pre-commercial phase and has developed a technology that allows for the local production of nitrogen-rich fertilizer from liquid organic substrates, such as livestock manure. By integrating nitrogen from the atmosphere into these substrates, N2 Applied's solution not only enhances the nitrogen content but also mitigates ammonia loss and reduces greenhouse gas emissions. The company operates its head office in Oslo/Asker and maintains a test center in Svene, with additional branches in Wageningen and York. N2 Applied's scalable process aims to eliminate the lengthy and costly supply chains associated with traditional fertilizer production, facilitating a more circular farming system. This approach not only provides farmers with cost-effective and environmentally friendly fertilizer but also contributes to on-farm reductions in methane and ammonia emissions.

Ganymed Robotics

Series B in 2023
Ganymed Robotics is a medical device company that develops robotics technologies for orthopedic surgeons, including a therapeutic device designed to improve precision in knee replacement procedures. Founded in 2018 and based in Paris, the company aims to enhance surgical accuracy, reduce operating times, and improve patient outcomes by integrating robotics into the orthopedic workflow.

Daze

Convertible Note in 2022
Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

iThera Medical

Venture Round in 2022
iThera Medical develops biomedical imaging technology based on photonic molecular imaging and multispectral optoacoustic tomography (MSOT) for preclinical and clinical applications. The company leverages the photoacoustic effect to visualize and quantify anatomical, functional, and molecular information in vivo, including deep tissue visualization and real-time imaging, enabling non-invasive assessment of tumors and inflammatory diseases. Founded in 2010 as a spin-off from Helmholtz Zentrum München, iThera Medical focuses on advancing MSOT technology for use in preclinical research and clinical trials, supporting researchers and clinicians in obtaining deeper insights into biological processes without invasive procedures.

Resistell

Series B in 2022
Founded in 2018, Resistell develops and markets a diagnostic device for phenotypic antibiotic susceptibility testing. Its unique method detects movement caused by living bacterial cells to determine bacterial resistance to antibiotics.

Alesi Surgical

Grant in 2022
Alesi Surgical Ltd. is a company based in Cardiff, United Kingdom, specializing in the development and commercialization of laparoscopic surgical smoke handling systems. Founded in 2009 as a spin-out from the Welsh Institute for Minimal Access Therapy, Alesi Surgical focuses on creating products that enhance the safety, efficiency, and outcomes of surgical procedures. Its innovative tools are portable and suitable for both laparoscopic and robot-assisted surgeries, utilizing electrostatic precipitation technology to eliminate surgical smoke and maintain a clear visual field during operations. The company distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia, leveraging its access to experienced surgeons and surgical trainers to identify challenges in surgical procedures and design effective solutions.

IonKraft

Grant in 2022
IonKraft, a German technology company, specializes in plasma coating for multi-material plastic containers. Their innovative plasma-enhanced chemical vapor deposition process enables recyclability of complex packaging, serving industries such as food, pharmaceuticals, cosmetics, and chemicals. By promoting material reduction and reuse, IonKraft aims to enhance performance while lowering costs, with support from the German Federal Ministry for Economic Affairs and Energy.

FOx Biosystems

Grant in 2022
FOx Biosystems is a biotechnology company focused on enhancing biomolecular interaction analysis for life science research and industry. Founded in 2017 by Filip Delport and Jeroen Lammertyn, and based in Temse, Oost-Vlaanderen, Belgium, the company specializes in developing custom applications, including probes and devices, to support various research needs. FOx Biosystems employs real-time, label-free analysis technology that offers significant advantages over traditional biomolecular analysis tools, such as ease of use, speed, and cost-effectiveness. This technology enables healthcare companies and researchers to obtain high-quality biomolecular data, including concentration measurements, affinity data, and kinetic data, ultimately aiming to transform the life sciences sector.

Inbrain Neuroelectronics

Venture Round in 2022
Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Nano4Imaging

Grant in 2022
Nano4Imaging GmbH, established in 2011 and located in Aachen, Germany, specializes in the development and production of contrast agents and devices designed for in-vivo imaging of medical implants and minimally invasive devices. The company offers a range of products, including MRWire EmeryGlide, a magnetic resonance imaging (MRI) conditional guidewire, and various coatings under the MagnaFy brand that enhance the visibility of devices in different imaging modalities, such as MRI, computed tomography (CT), and X-ray. These innovations facilitate navigation and monitoring during medical interventions, particularly in the treatment of cardiovascular diseases and in radiotherapy. By leveraging advanced nanotechnology, Nano4Imaging aims to improve the accuracy of patient monitoring and intervention outcomes.

Precisis

Grant in 2022
Precisis is a medical technology company founded in 2004 and headquartered in Heidelberg, Germany, focused on developing innovative devices for epilepsy treatment. The company designs a brain-computer interface device that delivers individualized brain stimulation by positioning beneath the scalp over the epileptic focus. The device enables deep, targeted stimulation of the affected brain region without direct contact with the skull or skull penetration, aiming to improve seizure control and quality of life for patients with epilepsy through precise anatomical targeting.

ABCDx

Venture Round in 2022
ABCDx is a Geneva-based company that develops and validates biomarker panels and related diagnostics for brain injury care. It aims to identify patients at risk of severe long-term complications after traumatic brain injury or stroke and to educate clinicians on using these tests. The company is building a platform that analyzes brain biomarkers from a finger-prick blood sample to enable rapid, point-of-care diagnosis of brain injuries, supporting timely treatment decisions. Founded in 2014 by researchers from the University of Geneva and related institutes, ABCDx translates biomarker discovery and clinical validation into practical tools for stroke and brain injury management.

LightnTec

Seed Round in 2022
LightnTec GmbH, founded in 2016 and headquartered in Karlsruhe, Germany, specializes in the development of innovative digital thin LED wallpapers. The company's flagship product, the Media-Screen-Matrix, is a lightweight, flexible, and highly transparent LED screen that can transform any façade into a dynamic media surface. Constructed from a thin-film PET substrate, this technology offers significant cost savings and energy efficiency, making it suitable for various applications, including installation on glass façades and billboards. The Media-Screen-Matrix is designed for outdoor use and can display images, videos, and text, providing clients with the ability to create immersive environments. Its modular design allows for customization in size and shape, enabling large-scale installations that can adapt to diverse architectural needs.

Inbrain Neuroelectronics

Grant in 2022
Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Dimenco

Venture Round in 2022
Dimenco develops and markets autostereoscopic 3D technology solutions. Founded in 2010, the company offers displays, components, software, content conversion services, and consultancy for professional and consumer applications.

Deep Render

Grant in 2022
Deep Render is a London-based AI startup spun out from Imperial College London's Department of Computing. It develops AI-powered video and image compression technology that leverages deep learning, density estimation, unsupervised learning, and quantum techniques to improve compression efficiency. The company has proprietary, patented technology in media and biological image compression, with state-of-the-art results delivering at least a 50% efficiency gain over previous standards.

Carmat

Grant in 2022
Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

ELEM Biotech

Pre Seed Round in 2022
ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human models through advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed a suite of simulation tools known as Alya Red. This platform operates on a Software-as-a-Service model and is designed for the medical device and pharmaceutical industries. Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients, utilizing high-performance computing, computational biomechanics, and data analysis. These virtual avatars enable biomedical companies and healthcare professionals to enhance diagnostics, plan treatments, optimize drug delivery, and improve medical devices.

Carmat

Post in 2022
Carmat is a French medtech company that specializes in the development and manufacturing of bioprosthetic artificial hearts. Founded in 2008 and headquartered in Vélizy-Villacoublay, the company creates biocompatible, auto-regulated total artificial hearts designed to closely mimic the human heart's structure, including both right and left ventricles. These devices are intended for patients suffering from chronic terminal heart failure classified as class IV by the New York Heart Association, as well as those experiencing acute terminal heart failure due to massive myocardial infarction. Carmat aims to provide a reliable and innovative therapeutic solution for heart failure patients who are ineligible for transplants and have exhausted other treatment options. In addition to the artificial hearts, the company develops the necessary power supply systems and remote diagnostic systems for these devices.

Cailabs

Series C in 2022
CAILabs SAS is a French deep tech company headquartered in Rennes, specializing in the design, development, and production of photonic solutions aimed at optimizing light utilization in various applications. Established in 2013, CAILabs focuses on innovative optical components, particularly through its patented Multi-Plane Light Conversion (MPLC) technology. The company provides a range of products, including mode multiplexers, light converters, and laser beam shaping solutions tailored for the telecommunications and industrial laser sectors. Its offerings are designed to enhance the performance of fiber optic networks and laser material processing, addressing critical challenges such as atmospheric turbulence and the need for efficient signal multiplexing. CAILabs aims to leverage its expertise and technological innovations to create reliable and cost-effective solutions for clients in the photonics industry.

ONO

Series A in 2022
Creating transformative change in urban mobility, making our cities cleaner and more enjoyable. We first focus on urban logistics, moving goods around the city in ways that are sustainable, efficient and cost-effective. Our vehicle and its modular platform system, with easily swappable modular units, meets the needs of city logistics. From moving food to flowers to furniture, the possibilities are endless. ONO’s founders, pioneer in e-mobility solutions, Beres Seelbach, former head of design at Mercedes and Volkswagen, Murat Günak, and light electric vehicle expert and engineer, Philipp Kahle, sought to rethink and reshape modern urban transportation. They put together a forward-thinking group of designers, engineers and creative thinkers who shared their vision of transforming urban mobility. ONO is a Berlin-based e-mobility company introducing a whole new category of emissions-free vehicle: the Pedal Assisted Transporter (PAT), combining the flexibility of a bicycle with the capacity and durability of a van. We offer environmentally friendly urban logistics solutions designed and optimised for cities of today.

ROSI

Series A in 2022
ROSI is a company based in Grenoble, France, focused on developing innovative technologies for the recycling and revalorization of raw materials within the photovoltaic industry. The company specializes in recovering ultra-pure silicon and other metals that are typically lost during the manufacturing of photovoltaic cells and at the end of a solar panel's life cycle. By addressing industrial waste generated during the solar wafer slicing process and capturing silicon fine particles lost during PV-silicon production, ROSI enables its clients to produce photovoltaic modules in a more sustainable and cost-effective manner.

APIX Analytics

Venture Round in 2022
Founded in 2014, APIX Analytics specializes in developing miniaturized multigas analyzers systems. These systems integrate silicon-based analytical chains such as sampling, gas injection, and mixture separation to enhance specificity, detection, identification, and quantification of compounds.

Positrigo

Series B in 2022
Positrigo develops and manufactures dedicated brain positron emission tomography (PET) scanners. Its mission is to make functional brain imaging accessible for early detection of neurodegenerative diseases like Alzheimer's, Lewy body dementia, vascular dementia, and frontotemporal dementia.

Ostoform

Grant in 2022
Ostoform is a Dublin, Ireland-based medical device company focused on ostomy skin health. It develops patented devices designed to manage skin complications for ostomy patients, including OSTOFORM, a mouldable seal that wraps around the stoma, and FLOWASSIST, which directs stoma output away from the skin. The technology is designed to prevent skin contact with corrosive output, reduce leakage, and improve skin health. The business originated as a spin-out from the University of Limerick and was established in 2016, leveraging patented technology to scale its solutions globally.

Fineheart

Grant in 2022
Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

AVVie

Grant in 2022
AVVie GmbH is a medical device startup that specializes in developing minimally invasive implants for heart valve repair, specifically targeting mitral regurgitation. This condition arises when the mitral valve leaflets fail to close properly, potentially leading to serious heart complications over time. The flagship product, the Mitral Butterfly® implant, is designed to be deployed via catheter, allowing for the repair of the mitral valve without the need for open-heart surgery. This innovative approach not only shortens hospitalization times but also expands treatment options for patients who may not be suitable candidates for traditional surgeries. The implant features a one-stage delivery system and a design that allows the leaflets to function normally after implantation, significantly improving upon existing solutions. The procedure to repair the valve is efficient, taking less than 12 minutes, and utilizes a combination of a nitinol stent and a polymer matrix to mimic conventional chordal repair techniques.

Fineheart

Series C in 2022
Fineheart is a France-based medical device company specializing in innovative technologies for cardiovascular care. It focuses on the development of implantable cardiac devices aimed at treating cardiovascular diseases. The company's flagship product is a novel, wirelessly powered, fully implantable mechanical circulatory support device. This device is designed to optimize cardiac output while preserving the heart's natural contractility, thereby enabling patients to restore normal cardiac function. Fineheart's technology aims to improve the quality of life for heart failure patients, allowing them to return to normal daily activities.

Tilkal

Venture Round in 2022
Tilkal develops a software infrastructure that organizes traceability across various supply chain stakeholders. Founded in 2017, the company is headquartered in Paris, France.

Tilkal

Grant in 2022
Tilkal develops a software infrastructure that organizes traceability across various supply chain stakeholders. Founded in 2017, the company is headquartered in Paris, France.

AugmedIT B.V.

Grant in 2022
AugmedIT B.V. is a medical software company founded in 2018 and located in Amsterdam, the Netherlands. The company specializes in developing augmented and mixed reality tools that enhance surgical procedures by enabling surgeons to create holograms of patients. AugmedIT's technology focuses on applications in neurosurgery, medical education, holographic visualization, and neuronavigation, aiming to improve precision and outcomes in medical practice through innovative visualization techniques.

IRUBIS

Convertible Note in 2022
Founded in Munich, Germany in 2017, IRUBIS specializes in manufacturing Mid-Infrared (MIR) spectrometers and Attenuated Total Reflection (ATR) crystals. The company combines semiconductor technology with infrared spectroscopy to develop devices for analyzing protein-based drugs. IRUBIS offers a real-time bioprocess monitoring system using MIR spectroscopy, which measures glucose and lactate online without contamination risk. They also provide ATR crystals and accessory solutions.

IRUBIS

Seed Round in 2022
Founded in Munich, Germany in 2017, IRUBIS specializes in manufacturing Mid-Infrared (MIR) spectrometers and Attenuated Total Reflection (ATR) crystals. The company combines semiconductor technology with infrared spectroscopy to develop devices for analyzing protein-based drugs. IRUBIS offers a real-time bioprocess monitoring system using MIR spectroscopy, which measures glucose and lactate online without contamination risk. They also provide ATR crystals and accessory solutions.

Vatorex

Convertible Note in 2022
Vatorex is a Swiss company that designs and develops electronic equipment to combat varroa mites and provides hive management and monitoring solutions for beekeeping. Its product line includes Varroa Solution, a heat-treatment system to kill varroa mites; the Full Hive Kit, for real-time hive monitoring and data collection; and Hive Manager, a mobile app for recording and organizing information about hives and yards. The company markets its products online and is based in Winterthur, Switzerland; it was founded in 2016. Vatorex employs a hyperthermic approach to improve honey bee health and protect colonies.

NICO.LAB

Grant in 2022
Born from the MRCLEAN trial, NICO.LAB was founded in 2015 as a spin-off from the Amsterdam University Medical Center. Our research background continues to drive our way of thinking. The team consists of researchers, developers and experienced medical specialists to ensure we align with our clients needs. We believe connecting human & artificial intelligence will revolutionize emergency care. Our cloud-based solution, StrokeViewer, automatically analyses brain CT scans and gives results within minutes. StrokeViewer empowers physicians in the emergency setting to provide patients with the right treatment in time.

LightnTec

Grant in 2022
LightnTec GmbH, founded in 2016 and headquartered in Karlsruhe, Germany, specializes in the development of innovative digital thin LED wallpapers. The company's flagship product, the Media-Screen-Matrix, is a lightweight, flexible, and highly transparent LED screen that can transform any façade into a dynamic media surface. Constructed from a thin-film PET substrate, this technology offers significant cost savings and energy efficiency, making it suitable for various applications, including installation on glass façades and billboards. The Media-Screen-Matrix is designed for outdoor use and can display images, videos, and text, providing clients with the ability to create immersive environments. Its modular design allows for customization in size and shape, enabling large-scale installations that can adapt to diverse architectural needs.

ELEM Biotech

Grant in 2022
ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human models through advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed a suite of simulation tools known as Alya Red. This platform operates on a Software-as-a-Service model and is designed for the medical device and pharmaceutical industries. Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients, utilizing high-performance computing, computational biomechanics, and data analysis. These virtual avatars enable biomedical companies and healthcare professionals to enhance diagnostics, plan treatments, optimize drug delivery, and improve medical devices.

Dimenco

Grant in 2022
Dimenco develops and markets autostereoscopic 3D technology solutions. Founded in 2010, the company offers displays, components, software, content conversion services, and consultancy for professional and consumer applications.

Circu Li-ion

Grant in 2022
Circu Li-ion is a Luxembourg-based startup specializing in automated battery disassembly and diagnostics. Its proprietary platform enables remanufacturing, reuse, and recycling of lithium-ion batteries at scale and cost-effectively. The platform comprises three core pillars: a battery library, application layer, and robotic disassembly systems. These systems reduce reliance on manual labor by 47%, achieve high robot autonomy (67%), enhance safety, and recover up to 95% of battery components for reuse or recycling.

ABCDx

Grant in 2022
ABCDx is a Geneva-based company that develops and validates biomarker panels and related diagnostics for brain injury care. It aims to identify patients at risk of severe long-term complications after traumatic brain injury or stroke and to educate clinicians on using these tests. The company is building a platform that analyzes brain biomarkers from a finger-prick blood sample to enable rapid, point-of-care diagnosis of brain injuries, supporting timely treatment decisions. Founded in 2014 by researchers from the University of Geneva and related institutes, ABCDx translates biomarker discovery and clinical validation into practical tools for stroke and brain injury management.

tozero

Pre Seed Round in 2022
Tozero, founded in July 2022 in Munich, Germany, by Sarah Fleischer and Dr. Ksenija Milicevic Neumann, specializes in lithium-ion battery recycling technology. The company aims to accelerate decarbonization efforts by developing a scalable and sustainable machine for recovering critical materials such as lithium, nickel, cobalt, graphite, and manganese from various battery types. By enabling industries to reintroduce these valuable raw materials into the supply chain, Tozero contributes to more sustainable practices in battery production and reduces dependency on virgin resources.

AMT Medical

Grant in 2022
AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.

Dawn Aerospace

Grant in 2022
Dawn Aerospace designs and manufactures reusable spacecraft and launch systems to enable frequent, sustainable access to space. The company develops same-day reusable launch vehicles that can operate with ordinary airspace and aircraft, without specialized space-launch infrastructure, and non-toxic, storable propulsion systems for satellites of all sizes, including CubeSats, offering higher performance while reducing reliance on toxic fuels. Dawn aims to provide end-to-end space transportation capabilities for deployment, positioning and return of spacecraft in a scalable, environmentally conscious manner. Founded in 2016, Dawn is based in New Zealand and the Netherlands, with research, manufacturing and testing facilities in Auckland and Delft.

Ganymed Robotics

Series B in 2022
Ganymed Robotics is a medical device company that develops robotics technologies for orthopedic surgeons, including a therapeutic device designed to improve precision in knee replacement procedures. Founded in 2018 and based in Paris, the company aims to enhance surgical accuracy, reduce operating times, and improve patient outcomes by integrating robotics into the orthopedic workflow.

Onward

Grant in 2022
Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.